Intraarterial ¹³¹I-MIBG therapy of neuroendocrine tumours with liver metastases

• References

• 1 Bestagno M, Pizzocaro C, Pagliaini R. et al. Results of [¹³¹I]metaiodobenzylguanidine treatment in metastatic carcinoid. J Nucl Biol Med 1991; 35: 343-345.
• 2 Bomanji JB, Wong W, Gaze MN. et al. Treatment of neuroendocrine tumours in adults with ¹³¹I-MIBG therapy. Clin Oncol (R Coll Radiol) 2003; 15: 193-198.
• 3 Brogsitter C, Pinkert J, Bredow J. et al. Enhanced tumor uptake in neuroendocrine tumors after in- traarterial application of ¹³¹I-MIBG. J Nucl Med 2005; 46: 2112-2116.
• 4 Fischer M. Therapy of pheochromocytoma with [¹³¹I]metaiodobenzylguanidine. J Nucl Biol Med 1991; 35: 292-294.
• 5 Giammarile F, Chiti A, Lassmann M. et al. EANM procedure guidelines for ¹³¹I-meta-iodobenzyl- guanidine therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1039-1047.
• 6 Hendlisz A, Flamen P, Van den Eynde M. et al. Locoregional and radioisotopic targeted treatment of neuroendocrine tumours. Acta Gastroenterol Belg 2009; 72: 44-48.
• 7 Hoefnagel CA, De Kraker J, Valdes Olmos RA, Voute PA. ¹³¹I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 1994; 15: 712-717.
• 8 Hoefnagel CA, Taal BG, Sivro F. et al. Enhancement of ¹³¹I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun 2000; 21: 755-761.
• 9 Tavris DR, Dey S, Albrecht-Gallauresi B. et al. Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II. J Invasive Cardiol 2005; 17: 644-650.